Table 4. Results of Fisher’s P-Value Test.
| Exposure Group | Study | Point Estimate (95% CI) | Statistic | P-Value Association | P-Value ofHarm | P-Value of Protection |
| Abacavir, Risk Per Year | ||||||
| Bedimo | 1.18 (0.92–1.50) | HR | 0.191 | 0.0922 | 0.908 | |
| Lang | 0.97 (0.86–1.10) | OR | 0.64 | 0.6862 | 0.3138 | |
| DAD 2008 | 1.14 (1.08–1.21) | RR | 0.0001 | 0.000003106 | 1 | |
| Summary | 0.000932618 | 2.66622E−05 | 0.8672322 | |||
| Abacavir, Risk of Recent Exposure | ||||||
| Choi | 1.64 (0.88–3.08) | HR | 0.1216353 | 0.06082 | 0.9391 | |
| Lundgren | 4.25 (1.39–13.00) | HR | 0.01117942 | 0.00559 | 0.9944 | |
| Lang | 1.62(0.93–2.81) | OR | 0.09 | 0.04361 | 0.9563 | |
| DAD 2008 | 1.9 (1.47–2.45) | RR | 0.0001 | 4.207E−07 | 1 | |
| Obel | 1.94 (1.01–3.72) | RR | 0.04632 | 0.02316 | 0.9768 | |
| Summary | 5.80959E−06 | 3.87002E−08 | 0.9999996 | |||
| Didanosine, Risk Per Year | ||||||
| Lang | 0.91 (0.82–1.01) | OR | 0.06 | 0.962 | 0.03803 | |
| DAD 2008 | 1.06 (1.01–1.12) | RR | 0.03 | 0.01357 | 0.9864 | |
| Summary | 0.01317594 | 0.06969235 | 0.1605729 | |||
| Didanosine, Risk of Recent Exposure | ||||||
| Lundgren | 1.89 (0.35–10.20) | HR | 0.4593097 | 0.2297 | 0.7703 | |
| Lang | 1.22 (0.65–2.30) | OR | 0.54 | 0.2687 | 0.7313 | |
| DAD 2008 | 1.49 (1.14–1.95) | RR | 0.003 | 0.001795 | 0.9982 | |
| Summary | 0.02539555 | 0.005714974 | 0.9792164 | |||
| Lamivudine, Risk of Recent Exposure | ||||||
| Lang | 1.42 (0.62–3.29) | OR | 0.41 | 0.2051 | 0.7949 | |
| DAD 2008 | 1.25 (.96–1.62) | RR | 0.1 | 0.04729 | 0.9527 | |
| Summary | 0.1719615 | 0.0546618 | 0.9678266 | |||
| Stavudine, Risk of Recent Exposure | ||||||
| Durand | 1.52 (1.04–2.21) | OR | 0.02944 | 0.01472 | 0.985 | |
| Lang | 0.96 (0.47–1.99) | OR | 0.92 | 0.5441 | 0.4559 | |
| DAD 2008 | 1.00 (0.76–1.32) | RR | 0.98 | 0.5 | 0.5 | |
| Summary | 0.2976478 | 0.08712864 | 0.810416 | |||
| Tenofovir, Risk of Recent Exposure | ||||||
| Lang | .058 (0.28–1.20) | OR | 0.14 | 0.9289 | 0.0711 | |
| DAD 2010 | 1.04 (0.91–1.18) | RR | 0.5540343 | 0.277 | 0.723 | |
| Summary | 0.2758579 | 0.6065952 | 0.203977 | |||
| Zidovudine, Risk of Recent Exposure | ||||||
| Lang | 1.04 (0.49–2.20) | OR | 0.93 | 0.4592 | 0.5408 | |
| DAD 2008 | 0.97 (0.76–1.25) | RR | 0.82 | 0.5948 | 0.4052 | |
| Summary | 0.969281 | 0.627603 | 0.5517924 | |||
| Protease Inhibitor, Risk of Recent Exposure | ||||||
| Iloeje | 1.76 (0.66–4.64) | HR | 0.2558345 | 0.1279 | 0.872 | |
| Kwong | 1.19 (1.01–1.40) | HR | 0.04 | 0.01838 | 0.98162 | |
| Barbaro | Not Reported | RR | 0.001 | Cannot Calculate | Cannot Calculate | |
| Holmberg | 4.92 (1.30–32.3) | OR | 0.04 | 0.02594 | 0.974 | |
| Rickerts | 2.61 (1.19–5.66) | OR | 0.01 | 0.007944 | 0.992 | |
| Daftary | 1.20 (0.50 –2.90) | OR | 0.6843204 | 0.3422 | 0.6577 | |
| Summary | 9.08759E−05 | 0.000538497 | 0.9995785 |
Results of Fisher’s P-value test, organized by drug and exposure definition. P-values are listed as overall p-value of association, and split into one-tailed p-values of harm and protection. Results are listed in bottom row of each group, denoted in bold text. Results are listed for any study group for which the Fisher’s test included more studies than the main meta-analysis. Note that risk of recent exposure represents the effect of exposure to the agent within the past 6 months relative to non-exposure in the past 6 months, and risk per year represents the effect of one additional year of exposure to the agent.